BLRX 外汇新闻
BioLineRx Collaborates With GenFleet To Advance Motixafortide In Pancreatic Ductal Adenocarcinoma
Biopharmaceutical company BioLineRx Ltd. (BLRX) announced Monday that it has entered into a collaboration agreement with China-based peer GenFleet Therapeutics to advance Motixafortide through a randomized Phase 2b clinical trial in pancreatic ductal adenocarcinoma, or PDAC.
RTTNews
|
914天前
